Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free VRCA Stock Alerts

Verrica Pharmaceuticals (VRCA) Financials

Verrica Pharmaceuticals logo
$6.26 -0.27 (-4.13%)
Closing price 04:00 PM Eastern
Extended Trading
$6.29 +0.03 (+0.48%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Verrica Pharmaceuticals

Annual Income Statements for Verrica Pharmaceuticals

This table shows Verrica Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.76 -21 -28 -43 -35 -24 -67 -77 -18
Consolidated Net Income / (Loss)		 -4.46 -21 -28 -43 -35 -24 -67 -77 -18
Net Income / (Loss) Continuing Operations		 -4.46 -21 -28 -43 -35 -24 -67 -77 -18
Total Pre-Tax Income 		-4.46 -21 -28 -43 -35 -24 -67 -77 -18
Total Operating Income		 -4.46 -22 -30 -40 -31 -21 -66 -66 -12
Total Gross Profit		 0.00 0.00 0.00 0.00 12 9.03 4.84 5.71 33
Total Revenue		 0.00 0.00 0.00 0.00 12 9.03 5.12 7.57 36
Operating Revenue		 - - - 0.00 12 9.03 5.12 7.57 36
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.29 1.85 2.19
Operating Cost of Revenue		 - - - - - 0.00 0.29 1.85 2.19
Total Operating Expenses		 4.46 22 30 40 43 30 71 72 46
Selling, General & Admin Expense		 0.73 9.05 15 25 27 17 47 59 35
Research & Development Expense		 3.73 13 15 16 16 12 20 12 8.86
Other Operating Expenses / (Income)		 - - - - - 0.73 0.46 0.89 1.25
Other Special Charges / (Income)		 - - - - - 0.00 2.54 0.08 0.25
Total Other Income / (Expense), net		 -0.00 1.23 1.87 -2.51 -4.17 -3.19 -1.22 -11 -5.70
Interest Expense		 0.00 - 0.00 3.03 4.30 3.61 3.96 9.41 9.28
Interest & Investment Income		 0.00 1.23 1.88 0.52 0.12 0.48 2.74 1.42 0.93
Other Income / (Expense), net		 0.00 -0.00 -0.00 - 0.00 -0.06 0.00 -2.67 2.65
Basic Earnings per Share		 ($1.56) ($1.41) ($1.13) ($1.71) ($1.30) ($0.72) ($1.48) ($14.78) ($1.68)
Weighted Average Basic Shares Outstanding		 2.85M 14.66M 24.90M 25.00M 27.04M 34.16M 45.34M 5.18M 10.65M
Diluted Earnings per Share		 ($1.56) ($1.41) ($1.13) ($1.71) ($1.30) ($0.72) ($1.48) ($14.78) ($1.68)
Weighted Average Diluted Shares Outstanding		 2.85M 14.66M 24.90M 25.00M 27.04M 34.16M 45.34M 5.18M 10.65M
Weighted Average Basic & Diluted Shares Outstanding		 2.85M 14.66M 24.90M 25.00M 27.04M 41.85M 42.42M 91.78M 17.18M

Quarterly Income Statements for Verrica Pharmaceuticals

This table shows Verrica Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -25 -25 -20 -17 -23 -16 -9.74 0.20 -0.27 -8.07 -9.68
Consolidated Net Income / (Loss)		 -25 -25 -20 -17 -23 -16 -9.74 0.20 -0.27 -8.07 -9.68
Net Income / (Loss) Continuing Operations		 -25 -25 -20 -17 -23 -16 -9.74 0.20 -0.27 -8.07 -9.65
Total Pre-Tax Income 		-25 -25 -20 -17 -23 -16 -9.74 0.20 -0.27 -8.07 -9.68
Total Operating Income		 -24 -23 -19 -15 -21 -11 -8.13 1.51 1.63 -7.19 -9.72
Total Gross Profit		 2.77 1.84 3.28 4.82 -2.13 -0.25 3.02 12 14 4.42 4.48
Total Revenue		 2.92 1.99 3.83 5.18 -1.78 0.34 3.44 13 14 5.09 5.02
Operating Revenue		 2.92 1.99 3.83 5.18 -1.78 0.34 3.44 13 14 5.09 5.02
Total Cost of Revenue		 0.15 0.14 0.55 0.36 0.35 0.60 0.42 0.34 0.75 0.68 0.54
Operating Cost of Revenue		 0.15 0.14 0.55 0.36 0.35 0.60 0.42 0.34 0.75 0.68 0.54
Total Operating Expenses		 27 25 22 20 19 11 11 11 12 12 14
Selling, General & Admin Expense		 20 17 16 17 16 9.88 8.85 8.85 9.40 8.12 9.99
Research & Development Expense		 6.51 5.32 4.95 3.32 2.41 1.17 2.28 1.85 2.21 2.52 3.86
Other Operating Expenses / (Income)		 0.13 0.13 0.59 0.18 0.08 0.03 0.01 0.15 0.36 0.73 0.35
Total Other Income / (Expense), net		 -0.89 -1.46 -1.73 -1.98 -2.16 -4.78 -1.61 -1.31 -1.90 -0.88 0.03
Interest Expense		 1.66 2.31 2.32 2.37 2.38 2.35 2.20 2.13 2.09 2.85 0.16
Interest & Investment Income		 0.82 0.79 0.60 0.39 0.22 0.21 0.34 0.23 0.16 0.21 0.20
Other Income / (Expense), net		 -0.05 0.05 -0.01 -0.01 -0.00 -2.63 0.25 0.60 0.03 1.76 -0.01
Other Gains / (Losses), net		 - - - - - - - - - - 0.03
Basic Earnings per Share		 ($0.54) ($0.55) ($0.44) ($3.70) ($4.88) ($0.18) ($1.03) $0.02 ($0.03) ($0.76) ($0.45)
Weighted Average Basic Shares Outstanding		 46.07M 45.34M 46.48M 4.65M 4.68M 51.81M 9.48M 9.49M 9.49M 10.65M 21.31M
Diluted Earnings per Share		 ($0.54) ($0.55) ($0.44) ($3.70) ($4.88) ($0.18) ($1.03) $0.02 ($0.03) ($0.76) ($0.45)
Weighted Average Diluted Shares Outstanding		 46.07M 45.34M 46.48M 4.65M 4.68M 51.81M 9.48M 9.49M 9.49M 10.65M 21.31M
Weighted Average Basic & Diluted Shares Outstanding		 42.06M 42.42M 42.42M 42.67M 45.60M 91.78M 92.49M 9.45M 9.49M 17.18M 17.18M

Annual Cash Flow Statements for Verrica Pharmaceuticals

This table details how cash moves in and out of Verrica Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 8.14 1.61 -1.03 1.45 5.07 19 35 -23 -16
Net Cash From Operating Activities		 -4.58 -18 -27 -30 -28 -19 -39 -61 -18
Net Cash From Continuing Operating Activities		 -4.58 -18 -27 -30 -28 -19 -39 -61 -18
Net Income / (Loss) Continuing Operations		 -4.46 -21 -28 -43 -35 -24 -67 -77 -18
Consolidated Net Income / (Loss)		 -4.46 -21 -28 -43 -35 -24 -67 -77 -18
Depreciation Expense		 0.00 0.02 0.06 0.04 0.24 0.45 0.53 0.34 0.13
Amortization Expense		 0.00 -0.44 -0.87 0.05 0.29 0.37 0.31 0.93 0.65
Non-Cash Adjustments To Reconcile Net Income		 0.08 2.26 3.18 11 7.50 6.31 18 12 4.87
Changes in Operating Assets and Liabilities, net		 -0.21 0.91 -1.57 1.64 -0.54 -1.31 9.93 1.89 -5.39
Net Cash From Investing Activities		 0.00 -80 26 -3.58 -1.00 54 -0.36 -0.02 0.00
Net Cash From Continuing Investing Activities		 0.00 -80 26 -3.58 -1.00 54 -0.36 -0.02 0.00
Purchase of Property, Plant & Equipment		 0.00 -0.77 -0.68 -1.47 -0.88 -0.30 -0.36 -0.03 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.01 0.00
Net Cash From Financing Activities		 13 99 0.42 35 34 -17 74 38 1.45
Net Cash From Continuing Financing Activities		 0.00 99 0.42 35 34 -17 74 38 1.45
Repayment of Debt		 - - 0.00 -0.09 -0.01 -44 -0.02 -2.06 -48
Issuance of Debt		 - - 0.00 34 4.98 0.00 44 0.00 0.00
Issuance of Common Equity		 0.00 86 - 0.00 28 27 30 40 50
Other Financing Activities, net		 0.00 0.01 0.42 0.86 0.56 0.00 -0.17 0.16 0.00
Cash Interest Paid		 0.00 - 0.00 1.88 2.85 1.79 3.15 7.23 5.17

Quarterly Cash Flow Statements for Verrica Pharmaceuticals

This table details how cash moves in and out of Verrica Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 29 -15 -21 -17 -8.97 23 -17 -14 5.70 9.05 -9.28
Net Cash From Operating Activities		 -15 -15 -20 -16 -8.56 -16 -13 -10 9.69 -4.59 -9.16
Net Cash From Continuing Operating Activities		 -15 -15 -20 -16 -8.57 -16 -13 -10 9.69 -4.59 -9.16
Net Income / (Loss) Continuing Operations		 -25 -25 -20 -17 -23 -16 -9.74 0.20 -0.27 -8.07 -9.68
Consolidated Net Income / (Loss)		 -25 -25 -20 -17 -23 -16 -9.74 0.20 -0.27 -8.07 -9.68
Depreciation Expense		 0.13 0.13 0.13 0.10 0.06 0.05 0.05 0.04 0.02 0.01 0.02
Amortization Expense		 0.08 0.09 0.21 0.23 0.28 0.20 0.16 0.16 0.16 0.18 0.18
Non-Cash Adjustments To Reconcile Net Income		 9.75 4.95 2.13 3.31 3.02 3.89 1.43 -6.97 9.99 0.42 1.06
Changes in Operating Assets and Liabilities, net		 0.03 4.94 -2.09 -2.80 11 -4.01 -4.57 -3.48 -0.22 2.87 -0.74
Net Cash From Investing Activities		 -0.07 -0.23 0.00 -0.01 -0.02 0.01 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -0.07 -0.23 0.00 -0.01 -0.02 0.01 0.00 - - - 0.00
Net Cash From Financing Activities		 44 -0.03 -0.66 -0.64 -0.40 39 -4.06 -4.16 -3.98 14 -0.12
Net Cash From Continuing Financing Activities		 44 -0.03 -0.66 -0.64 -0.40 39 -4.06 -4.16 -3.98 14 -0.12
Repayment of Debt		 - -0.02 -0.67 -0.79 -0.23 0.55 -4.06 -4.16 -3.71 -36 -0.11
Other Financing Activities, net		 - -0.18 0.00 0.15 -0.16 -0.92 0.00 - -0.28 0.28 -0.01
Cash Interest Paid		 1.32 1.83 1.84 1.85 1.80 1.73 1.54 1.44 1.38 0.82 0.02

Annual Balance Sheets for Verrica Pharmaceuticals

This table presents Verrica Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 9.08 92 68 74 80 45 82 54 47
Total Current Assets		 9.08 91 65 68 74 39 78 51 43
Cash & Equivalents		 8.66 10 9.24 11 16 34 70 46 30
Accounts Receivable		 - - - - 0.00 0.10 4.42 0.05 5.26
Inventories, net		 - - - - - 0.00 1.02 2.46 2.24
Prepaid Expenses		 0.42 1.34 2.97 2.18 3.97 4.36 2.55 2.31 2.80
Other Current Assets		 - - - - 0.00 0.39 - 0.03 2.10
Plant, Property, & Equipment, net		 0.00 0.26 2.09 3.10 3.89 3.89 1.05 0.59 0.21
Total Noncurrent Assets		 0.00 0.50 1.35 3.40 1.90 1.72 3.02 2.37 4.38
Noncurrent Note & Lease Receivables		 - - - - - 0.00 1.41 1.15 1.11
Other Noncurrent Operating Assets		 0.00 0.50 1.35 3.40 1.90 1.72 1.61 1.21 3.27
Total Liabilities & Shareholders' Equity		 9.08 92 68 74 80 45 82 54 47
Total Liabilities		 0.62 2.48 3.41 41 48 4.69 62 64 22
Total Current Liabilities		 0.62 2.48 3.35 39 46 3.46 17 29 16
Accounts Payable		 0.17 0.96 1.19 0.35 0.85 0.51 2.46 1.90 2.07
Accrued Expenses		 0.45 1.52 2.04 3.11 3.27 2.66 14 14 13
Current Deferred Revenue		 - - 0.00 0.50 - - - 0.00 0.78
Other Current Liabilities		 - - 0.13 0.20 0.25 0.30 0.70 0.67 0.75
Total Noncurrent Liabilities		 0.00 0.00 0.06 1.69 1.47 1.23 45 35 5.95
Capital Lease Obligations		 - - - - 0.02 0.00 1.03 0.77 0.64
Other Noncurrent Operating Liabilities		 - - 0.06 1.69 1.45 1.23 0.91 3.23 5.31
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -7.04 89 65 33 33 40 20 -9.86 25
Total Preferred & Common Equity		 -7.04 89 65 33 33 40 20 -9.86 25
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -7.04 89 65 33 33 40 20 -9.86 25
Common Stock		 5.39 123 127 137 172 203 250 297 350
Retained Earnings		 -12 -33 -61 -104 -139 -163 -230 -307 -325
Treasury Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Verrica Pharmaceuticals

This table presents Verrica Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 97 66 52 33 42 39 41 39
Total Current Assets		 92 61 47 28 39 37 36 34
Cash & Equivalents		 84 49 32 23 30 15 21 21
Accounts Receivable		 4.07 7.59 10 0.08 5.65 9.19 7.33 7.72
Inventories, net		 0.28 2.50 2.70 2.58 2.46 2.52 2.30 1.97
Prepaid Expenses		 3.07 2.34 2.48 2.56 1.77 1.49 3.59 2.37
Other Current Assets		 0.00 - - - - 8.18 1.96 1.46
Plant, Property, & Equipment, net		 3.56 0.94 0.71 0.65 0.54 0.32 0.23 0.19
Total Noncurrent Assets		 1.87 3.99 3.98 4.09 2.17 2.01 4.40 4.47
Noncurrent Note & Lease Receivables		 - 2.46 2.52 2.64 1.03 0.95 1.05 1.01
Other Noncurrent Operating Assets		 1.87 1.53 1.46 1.45 1.14 1.07 3.35 3.46
Total Liabilities & Shareholders' Equity		 97 66 52 33 42 39 41 39
Total Liabilities		 55 65 65 67 61 57 58 23
Total Current Liabilities		 11 19 20 21 29 29 29 16
Accounts Payable		 1.93 2.53 1.15 0.97 1.44 2.32 1.59 2.19
Accrued Expenses		 9.10 16 18 19 14 13 13 12
Current Deferred Revenue		 - - - - - 0.48 1.56 1.03
Other Current Liabilities		 0.35 1.01 1.05 1.16 0.65 0.65 0.70 0.74
Total Noncurrent Liabilities		 43 45 45 46 31 27 29 6.51
Capital Lease Obligations		 0.08 1.76 1.76 1.98 0.66 - - 0.55
Other Noncurrent Operating Liabilities		 0.99 0.83 0.74 0.67 2.89 2.79 7.41 5.97
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 42 1.51 -13 -34 -19 -17 -17 16
Total Preferred & Common Equity		 42 1.51 -13 -34 -19 -17 -17 16
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 42 1.51 -13 -34 -19 -17 -17 16
Common Stock		 248 252 255 257 298 299 300 351
Retained Earnings		 -206 -251 -268 -291 -317 -317 -317 -335
Treasury Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Verrica Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Verrica Pharmaceuticals' official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 25,696,371.00 25,775,164.00 25,865,542.00 27,519,053.00 41,094,053.00 42,064,553.00 - 9,490,035.00
DEI Adjusted Shares Outstanding		 0.00 2,569,637.00 2,577,516.00 2,586,554.00 2,751,905.00 4,109,405.00 4,206,455.00 - 9,490,035.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -8.04 -10.94 -16.51 -12.75 -5.96 -15.93 - -1.88
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -24.73% -43.27% 47.66% 370.22%
EBITDA Growth		 0.00% -400.20% -38.56% -29.78% 24.25% 32.41% -216.27% -3.66% 86.99%
EBIT Growth		 0.00% -390.89% -37.50% -33.56% 23.08% 30.91% -207.95% -4.27% 86.09%
NOPAT Growth		 0.00% -390.87% -37.49% -33.58% 23.08% 31.10% -208.79% -0.24% 81.52%
Net Income Growth		 0.00% -363.06% -36.61% -51.36% 17.83% 30.20% -173.59% -14.31% 76.64%
EPS Growth		 0.00% 9.62% 19.86% -51.33% 23.98% 44.62% -105.56% 0.00% 88.63%
Operating Cash Flow Growth		 0.00% -290.01% -53.34% -10.21% 8.69% 32.38% -106.85% -57.94% 71.07%
Free Cash Flow Firm Growth		 0.00% 0.00% -61.49% -14.43% 18.58% 26.61% -105.82% -17.86% 62.33%
Invested Capital Growth		 0.00% -93.88% 888.95% -5.57% 39.88% 45.45% -202.15% -95.45% 58.60%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.76% 59.93% -17.85% 15.40%
EBITDA Q/Q Growth		 0.00% 0.00% 1.93% -11.16% 11.46% 8.83% -35.25% 11.91% 49.38%
EBIT Q/Q Growth		 0.00% 0.00% 0.64% -11.19% 10.34% 9.33% -34.66% 11.67% 47.44%
NOPAT Q/Q Growth		 0.00% 0.00% 0.65% -11.19% 10.34% 9.58% -34.66% 15.10% 25.71%
Net Income Q/Q Growth		 0.00% 0.00% -0.21% -14.30% 8.92% 12.84% -38.67% 9.90% 31.24%
EPS Q/Q Growth		 0.00% 0.00% -169.05% -14.00% 10.96% 30.77% -52.58% 20.00% 38.69%
Operating Cash Flow Q/Q Growth		 0.00% -39.44% -5.02% 6.54% -10.40% 16.72% -32.91% -2.62% 39.43%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -3.54% 7.29% 12.49% -17.16% 3.85% 20.25%
Invested Capital Q/Q Growth		 0.00% 0.00% 421.39% 24.11% 46.40% 8.45% -1,333.54% 1.90% -17.27%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 94.36% 75.51% 93.84%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -253.08% -227.28% -1,267.04% -889.48% -24.62%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -257.57% -235.78% -1,283.35% -871.25% -34.25%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -257.57% -236.43% -1,283.35% -906.25% -26.82%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -292.33% -271.11% -1,307.47% -1,012.15% -50.27%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.02% 100.02% 100.00%
Interest Burden Percent		 100.04% 94.37% 93.76% 106.25% 113.50% 114.67% 101.86% 111.66% 187.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -637.18% -306.73% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -591.46% -276.28% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 530.22% 239.31% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.66% -42.18% -36.53% -87.13% -106.97% -67.42% -224.08% -1,546.58% -240.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -815.01% -959.33% -670.43% -343.77% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -40.07% -34.21% -104.12% -101.03% -18.84%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -45.48% -39.23% -106.07% -112.84% -35.33%
Return on Common Equity (ROCE)		 43.79% -35.50% -36.53% -87.13% -106.97% -67.42% -224.08% -1,546.58% -240.35%
Return on Equity Simple (ROE_SIMPLE)		 63.33% -23.09% -43.39% -129.43% -107.59% -61.17% -338.99% 776.66% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.12 -15 -21 -28 -22 -15 -46 -46 -8.53
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -180.30% -165.05% -898.35% -609.88% -23.97%
Net Nonoperating Expense Percent (NNEP)		 -15.46% -10.83% -9.42% -31.61% -45.73% -30.45% -69.97% -223.08% -60.09%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -72.30% -132.49% -33.60%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.64% 24.49% 6.16%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 224.83% 192.70% 923.20% 777.45% 99.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 132.74% 135.05% 396.08% 156.49% 24.89%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 357.57% 335.78% 1,377.71% 946.76% 128.09%
Earnings before Interest and Taxes (EBIT)		 -4.46 -22 -30 -40 -31 -21 -66 -69 -9.54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.46 -22 -31 -40 -30 -21 -65 -67 -8.76
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.34 6.30 9.03 7.73 2.82 15.58 0.00 3.19
Price to Tangible Book Value (P/TBV)		 0.00 2.34 6.30 9.03 7.73 2.82 15.58 0.00 3.19
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 21.01 12.51 60.09 4.22 2.22
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 115.93 94.51 56.42 13.67 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 18.62 8.72 55.09 4.00 1.39
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 1.07 1.28 0.00 2.22 -4.53 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 2.22 -3.22 0.03
Financial Leverage		 -1.02 -1.01 -0.98 -0.94 -0.90 -0.87 -1.00 -2.76 -2.09
Leverage Ratio		 1.07 1.03 1.04 1.45 2.35 1.72 2.11 13.71 6.80
Compound Leverage Factor		 1.07 0.97 0.97 1.55 2.67 1.97 2.15 15.30 12.76
Debt to Total Capital		 0.00% 0.00% 0.00% 51.71% 56.13% 0.00% 68.96% 128.31% 2.53%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 51.71% 56.10% 0.00% 0.00% 37.15% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 68.96% 91.16% 2.53%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 183.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -83.16% 100.00% 100.00% 48.30% 43.87% 100.00% 31.04% -28.31% 97.47%
Debt to EBITDA		 0.00 0.00 0.00 -0.88 -1.37 0.00 -0.68 -0.66 -0.07
Net Debt to EBITDA		 0.00 0.00 0.00 0.75 0.94 0.00 0.40 0.02 3.37
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.68 -0.47 -0.07
Debt to NOPAT		 0.00 0.00 0.00 -1.26 -1.93 0.00 -0.95 -0.97 -0.08
Net Debt to NOPAT		 0.00 0.00 0.00 1.07 1.32 0.00 0.56 0.04 3.46
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.95 -0.69 -0.08
Altman Z-Score		 70.63 50.60 70.46 1.05 0.05 8.93 -2.67 -11.19 -6.79
Noncontrolling Interest Sharing Ratio		 183.16% 15.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 14.75 36.80 19.39 1.71 1.61 11.31 4.55 1.76 2.59
Quick Ratio		 14.06 36.26 18.51 1.66 1.53 9.94 4.34 1.60 2.15
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -15 -24 -28 -23 -17 -34 -41 -15
Operating Cash Flow to CapEx		 0.00% -2,309.30% -4,018.77% -2,054.90% -3,123.67% -6,175.50% -10,656.63% -320,668.42% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -9.22 -5.30 -4.63 -8.68 -4.31 -1.65
Operating Cash Flow to Interest Expense		 -2,291.50 0.00 0.00 -9.96 -6.42 -5.17 -9.74 -6.47 -1.90
Operating Cash Flow Less CapEx to Interest Expense		 -2,291.50 0.00 0.00 -10.44 -6.63 -5.25 -9.83 -6.48 -1.90
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.16 0.14 0.08 0.11 0.70
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 2.27 3.37 13.41
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.06 0.93
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 3.43 2.32 2.07 9.22 89.17
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.85 1.10
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 160.81 108.38 27.23
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 343.23 391.23
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 1,876.15 429.41 330.37
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -1,715.34 22.20 88.09
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -0.20 -0.38 3.00 2.83 3.96 5.76 -5.88 -12 -4.76
Invested Capital Turnover		 0.00 0.00 0.00 0.00 3.53 1.86 -82.65 -0.87 -4.38
Increase / (Decrease) in Invested Capital		 0.00 -0.18 3.38 -0.17 1.13 1.80 -12 -5.62 6.74
Enterprise Value (EV)		 82 120 348 268 223 79 282 30 49
Market Capitalization		 75 209 410 298 252 113 308 32 79
Book Value per Share		 ($2.47) $3.48 $2.52 $1.28 $1.18 $0.97 $0.47 ($0.22) $2.61
Tangible Book Value per Share		 ($2.47) $3.48 $2.52 $1.28 $1.18 $0.97 $0.47 ($0.22) $2.61
Total Capital		 8.47 89 65 68 74 40 64 35 25
Total Debt		 0.00 0.00 0.00 35 42 0.00 44 45 0.64
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.02 0.00 44 32 0.64
Net Debt		 -8.66 -90 -62 -30 -29 -34 -26 -1.64 -30
Capital Expenditures (CapEx)		 0.00 0.77 0.68 1.47 0.88 0.30 0.36 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.20 -1.13 -0.39 -1.98 -0.39 1.38 -9.04 -11 -4.05
Debt-free Net Working Capital (DFNWC)		 8.47 89 62 63 70 36 61 35 26
Net Working Capital (NWC)		 8.47 89 62 28 28 36 61 22 26
Net Nonoperating Expense (NNE)		 1.34 5.33 7.15 15 13 9.58 21 30 9.36
Net Nonoperating Obligations (NNO)		 -8.66 -90 -62 -30 -29 -34 -26 -1.64 -30
Total Depreciation and Amortization (D&A)		 0.00 -0.41 -0.81 0.09 0.54 0.83 0.84 1.27 0.78
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -3.23% 15.31% -176.44% -148.35% -11.37%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 583.05% 394.77% 1,180.84% 463.98% 73.37%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 235.61% 394.77% 1,180.84% 292.98% 73.37%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.56) ($1.41) ($1.13) ($1.71) ($1.30) ($0.72) ($1.48) ($1.48) ($1.68)
Adjusted Weighted Average Basic Shares Outstanding		 2.85M 25.71M 25.81M 25.44M 27.52M 34.16M 45.34M 51.81M 10.65M
Adjusted Diluted Earnings per Share		 ($1.56) ($1.41) ($1.13) ($1.71) ($1.30) ($0.72) ($1.48) ($1.48) ($1.68)
Adjusted Weighted Average Diluted Shares Outstanding		 2.85M 25.71M 25.81M 25.44M 27.52M 34.16M 45.34M 51.81M 10.65M
Adjusted Basic & Diluted Earnings per Share		 ($1.56) ($1.41) ($1.13) ($1.71) ($1.30) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.85M 14.66M 24.90M 25.00M 27.04M 41.85M 42.42M 91.78M 17.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.12 -15 -21 -28 -22 -15 -44 -46 -8.36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -180.30% -165.05% -863.69% -609.11% -23.49%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -292.33% -271.11% -1,307.20% -1,011.92% -50.27%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -2,228.50 0.00 0.00 -13.24 -7.20 -5.92 -16.60 -7.29 -1.03
NOPAT to Interest Expense		 -1,559.95 0.00 0.00 -9.27 -5.04 -4.13 -11.62 -4.90 -0.92
EBIT Less CapEx to Interest Expense		 -2,228.50 0.00 0.00 -13.73 -7.40 -6.00 -16.69 -7.29 -1.03
NOPAT Less CapEx to Interest Expense		 -1,559.95 0.00 0.00 -9.76 -5.24 -4.21 -11.71 -4.90 -0.92
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -38.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Verrica Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Verrica Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 42,064,553.00 42,064,553.00 42,418,553.00 42,420,053.00 42,668,553.00 - 91,779,993.00 92,490,993.00 9,445,768.00 9,490,035.00 17,178,786.00
DEI Adjusted Shares Outstanding		 4,206,455.00 4,206,455.00 4,241,855.00 4,242,005.00 4,266,855.00 - 9,177,999.00 9,249,099.00 9,445,768.00 9,490,035.00 17,178,786.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.90 -5.85 -4.79 -4.05 -5.36 - -1.06 0.02 -0.03 -0.85 -0.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -64.94% 2,823.53% 10,240.54% 2,744.51% -161.06% -82.70% -10.12% 145.35% 905.39% 1,380.23% 46.06%
EBITDA Growth		 -1,423.51% -281.10% -165.28% -30.40% 14.29% 39.71% 58.03% 115.50% 109.06% 62.03% -24.27%
EBIT Growth		 -1,749.48% -271.59% -162.52% -30.95% 13.61% 39.18% 57.68% 113.85% 108.02% 61.36% -23.45%
NOPAT Growth		 -1,256.21% -272.40% -162.36% -30.91% 13.43% 50.69% 56.29% 114.19% 107.86% 36.97% -19.50%
Net Income Growth		 -29,981.93% -314.94% -208.56% -56.38% 7.83% 34.18% 52.08% 101.19% 98.80% 50.17% 0.62%
EPS Growth		 0.00% -1,275.00% -193.33% -56.38% 7.83% 67.27% 52.08% 101.19% 99.39% 75.72% 56.31%
Operating Cash Flow Growth		 -911.56% -192.83% -334.58% -250.35% 42.22% -10.73% 36.45% 38.60% 213.17% 71.42% 27.72%
Free Cash Flow Firm Growth		 -928.32% 25.97% -22.53% -132.98% 80.75% 47.91% 69.32% 63.02% -184.55% -396.56% -495.42%
Invested Capital Growth		 -91.02% -202.15% -157.66% -375.00% -2,557.65% -95.45% -144.01% 711.33% 65.37% 58.60% 41.93%
Revenue Q/Q Growth		 1,502.75% -31.85% 92.45% 35.31% -134.40% 119.32% 899.71% 269.35% 12.93% -64.50% -1.36%
EBITDA Q/Q Growth		 -108.23% 3.73% 20.11% 18.57% -36.88% 32.29% 44.45% 130.07% -19.99% -384.12% -81.78%
EBIT Q/Q Growth		 -106.33% 3.67% 19.39% 18.26% -36.12% 32.19% 43.98% 126.75% -21.17% -427.03% -78.99%
NOPAT Q/Q Growth		 -105.90% 3.26% 19.61% 18.24% -36.16% 44.89% 28.75% 126.53% -24.58% -542.04% -35.08%
Net Income Q/Q Growth		 -125.68% 0.76% 17.40% 15.47% -33.02% 29.13% 39.87% 102.09% -234.31% -2,846.72% -19.92%
EPS Q/Q Growth		 -125.00% -1.85% 20.00% 15.47% -33.02% 63.27% 39.87% 102.09% -250.00% -2,433.33% 40.79%
Operating Cash Flow Q/Q Growth		 -217.22% 2.05% -37.50% 17.99% 47.68% -87.71% 21.08% 20.77% 196.43% -147.40% -99.59%
Free Cash Flow Firm Q/Q Growth		 -186.92% 61.77% -16.51% -82.32% 76.29% -3.41% 31.38% -119.79% -82.44% -80.46% 17.72%
Invested Capital Q/Q Growth		 83.46% -1,333.54% 52.04% 74.66% -1,539.58% 1.90% 40.12% 163.48% -192.88% -17.27% 16.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 95.03% 92.76% 85.73% 93.05% 0.00% -73.26% 87.70% 97.32% 94.74% 86.74% 89.17%
EBITDA Margin		 -814.43% -1,150.40% -477.52% -287.37% 0.00% -4,008.14% -222.97% 18.15% 12.86% -102.95% -189.71%
Operating Margin		 -819.92% -1,163.83% -486.12% -293.72% 0.00% -3,316.86% -236.41% 11.89% 11.34% -141.24% -193.41%
EBIT Margin		 -821.63% -1,161.32% -486.41% -293.82% 0.00% -4,081.69% -229.02% 16.59% 11.58% -106.68% -193.57%
Profit (Net Income) Margin		 -850.26% -1,238.13% -531.39% -331.97% 0.00% -4,709.88% -283.28% 1.61% -1.91% -158.56% -192.75%
Tax Burden Percent		 100.00% 100.06% 100.00% 100.00% 100.00% 100.11% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.48% 106.55% 109.25% 112.98% 110.41% 115.27% 123.69% 9.68% -16.50% 148.64% 99.58%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -635.42% 0.00% -2,927.57% 0.00% 0.00% 0.00% 0.00% 95.62% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -615.59% 0.00% -2,904.82% 0.00% 0.00% 0.00% 0.00% 88.04% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 574.67% 0.00% 2,814.11% 0.00% 0.00% 0.00% 0.00% -98.50% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -60.76% -224.08% -113.46% -412.98% -2,059.89% -1,546.58% 773.26% -2.87% 101.83% -240.35% 1,414.20%
Cash Return on Invested Capital (CROIC)		 -1,014.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -736.67% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -35.99% -94.22% -64.25% -71.56% 0.00% -455.05% -30.31% 5.35% 9.67% -74.96% -177.69%
Return on Assets (ROA)		 -37.24% -100.45% -70.20% -80.85% 0.00% -525.08% -37.49% 0.52% -1.60% -111.41% -176.94%
Return on Common Equity (ROCE)		 -60.76% -224.08% -113.46% -412.98% -2,059.89% -1,546.58% 773.26% -2.87% 101.83% -240.35% 1,414.20%
Return on Equity Simple (ROE_SIMPLE)		 -114.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -16 -13 -11 -14 -7.99 -5.69 1.51 1.14 -5.03 -6.80
NOPAT Margin		 -573.94% -814.68% -340.28% -205.61% 0.00% -2,321.80% -165.48% 11.89% 7.94% -98.87% -135.39%
Net Nonoperating Expense Percent (NNEP)		 -19.83% -28.10% -22.75% -30.75% -85.83% -60.21% 110.08% 7.58% 8.00% -19.52% -68.90%
Return On Investment Capital (ROIC_SIMPLE)		 - -25.44% -28.23% -34.10% -128.99% -22.93% -25.06% 7.64% 6.68% -19.83% -40.96%
Cost of Revenue to Revenue		 4.97% 7.24% 14.27% 6.95% 0.00% 173.26% 12.30% 2.68% 5.26% 13.26% 10.83%
SG&A Expenses to Revenue		 687.49% 854.88% 427.05% 319.14% 0.00% 2,871.51% 257.28% 69.69% 65.55% 159.41% 198.87%
R&D to Revenue		 223.17% 267.66% 129.33% 64.11% 0.00% 339.53% 66.41% 14.53% 15.37% 49.49% 76.85%
Operating Expenses to Revenue		 914.95% 1,256.59% 571.85% 386.77% 0.00% 3,243.60% 324.11% 85.44% 83.40% 227.99% 282.58%
Earnings before Interest and Taxes (EBIT)		 -24 -23 -19 -15 -21 -14 -7.88 2.11 1.66 -5.43 -9.72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -23 -18 -15 -20 -14 -7.67 2.31 1.85 -5.24 -9.53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.86 15.58 166.52 0.00 0.00 0.00 0.00 0.00 0.00 3.19 5.66
Price to Tangible Book Value (P/TBV)		 3.86 15.58 166.52 0.00 0.00 0.00 0.00 0.00 0.00 3.19 5.66
Price to Revenue (P/Rev)		 51.01 60.09 28.17 22.23 6.72 4.22 5.65 3.33 1.32 2.22 2.45
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 254.92 0.00 0.00 0.00 0.00 0.00 0.00 16.22 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 37.95 55.09 27.69 23.14 9.14 4.00 7.28 4.82 1.74 1.39 1.91
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.00 2.22 29.58 -3.35 -1.33 -4.53 -2.22 -2.13 -2.00 0.03 0.03
Long-Term Debt to Equity		 1.00 2.22 29.58 -3.35 -1.33 -3.22 -1.53 -1.41 -1.27 0.03 0.03
Financial Leverage		 -0.93 -1.00 -0.97 -1.01 -2.36 -2.76 -0.43 -1.12 -0.69 -2.09 3.32
Leverage Ratio		 1.68 2.11 2.03 2.71 15.76 13.71 -6.36 -2.96 -1.44 6.80 -32.12
Compound Leverage Factor		 1.74 2.25 2.22 3.07 17.40 15.80 -7.86 -0.29 0.24 10.11 -31.98
Debt to Total Capital		 50.11% 68.96% 96.73% 142.61% 403.05% 128.31% 181.80% 188.45% 200.02% 2.53% 3.29%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 37.15% 56.46% 64.11% 73.12% 0.00% 0.00%
Long-Term Debt to Total Capital		 50.11% 68.96% 96.73% 142.61% 403.05% 91.16% 125.34% 124.34% 126.89% 2.53% 3.29%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 49.89% 31.04% 3.27% -42.61% -303.05% -28.31% -81.80% -88.45% -100.02% 97.47% 96.71%
Debt to EBITDA		 -0.89 -0.68 -0.58 -0.56 -0.59 -0.66 -0.73 -0.94 -1.97 -0.07 -0.05
Net Debt to EBITDA		 0.87 0.40 0.06 -0.16 -0.29 0.02 -0.21 -0.55 -0.75 3.37 1.89
Long-Term Debt to EBITDA		 -0.89 -0.68 -0.58 -0.56 -0.59 -0.47 -0.50 -0.62 -1.25 -0.07 -0.05
Debt to NOPAT		 -1.24 -0.95 -0.82 -0.79 -0.83 -0.97 -1.06 -1.37 -2.97 -0.08 -0.06
Net Debt to NOPAT		 1.22 0.56 0.08 -0.22 -0.41 0.04 -0.30 -0.81 -1.13 3.46 2.08
Long-Term Debt to NOPAT		 -1.24 -0.95 -0.82 -0.79 -0.83 -0.69 -0.73 -0.91 -1.88 -0.08 -0.06
Altman Z-Score		 -0.97 -0.95 -3.00 -4.44 -13.35 -7.87 -10.27 -10.03 -9.32 -6.50 -8.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.06 4.55 3.17 2.36 1.34 1.76 1.34 1.26 1.25 2.59 2.10
Quick Ratio		 7.77 4.34 2.92 2.10 1.10 1.60 1.20 0.84 0.98 2.15 1.75
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -4.55 -5.30 -9.67 -2.29 -2.37 -1.63 -3.58 -6.52 -12 -9.69
Operating Cash Flow to CapEx		 -22,786.15% -6,390.75% 0.00% -148,709.09% -53,487.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -7.19 -1.97 -2.29 -4.08 -0.97 -1.01 -0.74 -1.68 -3.12 -4.14 -60.55
Operating Cash Flow to Interest Expense		 -8.94 -6.29 -8.60 -6.91 -3.60 -6.84 -5.75 -4.71 4.63 -1.61 -57.27
Operating Cash Flow Less CapEx to Interest Expense		 -8.98 -6.39 -8.60 -6.91 -3.61 -6.84 -5.75 -4.71 4.63 -1.61 -57.27
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.08 0.13 0.24 0.14 0.11 0.13 0.32 0.84 0.70 0.92
Accounts Receivable Turnover		 1.43 2.27 2.33 2.68 4.43 3.37 1.08 1.52 8.32 13.41 5.56
Inventory Turnover		 0.00 0.00 0.00 0.00 0.98 1.06 0.70 0.65 0.86 0.93 1.04
Fixed Asset Turnover		 0.85 2.07 3.76 6.32 4.38 9.22 9.74 28.69 70.39 89.17 102.09
Accounts Payable Turnover		 0.00 0.19 0.54 0.75 0.97 0.85 0.87 0.99 1.66 1.10 1.27
Days Sales Outstanding (DSO)		 255.81 160.81 156.64 136.22 82.35 108.38 336.76 240.80 43.88 27.23 65.70
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 372.95 343.23 523.03 557.75 422.18 391.23 349.77
Days Payable Outstanding (DPO)		 0.00 1,876.15 677.98 489.77 376.59 429.41 418.80 370.44 220.33 330.37 286.89
Cash Conversion Cycle (CCC)		 255.81 -1,715.34 -521.34 -353.55 78.71 22.20 440.98 428.10 245.73 88.09 128.58
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.48 -5.88 -2.82 -0.72 -12 -12 -6.89 4.37 -4.06 -4.76 -4.00
Invested Capital Turnover		 1.11 -82.65 8.60 -61.13 -1.64 -0.87 -1.48 8.04 -3.91 -4.38 -6.83
Increase / (Decrease) in Invested Capital		 -4.83 -12 -7.72 -0.98 -12 -5.62 -4.06 5.09 7.66 6.74 2.89
Enterprise Value (EV)		 122 282 247 322 84 30 52 71 54 49 71
Market Capitalization		 163 308 251 309 62 32 41 49 41 79 91
Book Value per Share		 $1.01 $0.47 $0.04 ($0.31) ($0.80) ($0.22) ($0.20) ($0.19) ($1.80) $2.61 $0.93
Tangible Book Value per Share		 $1.01 $0.47 $0.04 ($0.31) ($0.80) ($0.22) ($0.20) ($0.19) ($1.80) $2.61 $0.93
Total Capital		 85 64 46 31 11 35 23 20 17 25 17
Total Debt		 42 44 45 45 45 45 41 37 34 0.64 0.55
Total Long-Term Debt		 42 44 45 45 45 32 28 25 22 0.64 0.55
Net Debt		 -42 -26 -4.33 13 22 -1.64 12 22 13 -30 -20
Capital Expenditures (CapEx)		 0.07 0.23 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.96 -9.04 -6.93 -4.66 -16 -11 -6.70 4.84 -1.27 -4.05 -2.69
Debt-free Net Working Capital (DFNWC)		 80 61 42 27 7.16 35 23 20 20 26 18
Net Working Capital (NWC)		 80 61 42 27 7.16 22 10 7.56 7.37 26 18
Net Nonoperating Expense (NNE)		 8.06 8.42 7.31 6.54 8.37 8.22 4.05 1.31 1.41 3.04 2.88
Net Nonoperating Obligations (NNO)		 -42 -26 -4.33 13 22 -1.64 12 22 13 -30 -20
Total Depreciation and Amortization (D&A)		 0.21 0.22 0.34 0.33 0.34 0.25 0.21 0.20 0.18 0.19 0.19
Debt-free, Cash-free Net Working Capital to Revenue		 -123.50% -176.44% -77.73% -33.53% -171.53% -148.35% -93.27% 32.89% -4.13% -11.37% -7.24%
Debt-free Net Working Capital to Revenue		 2,507.83% 1,180.84% 471.35% 196.05% 77.75% 463.98% 318.97% 137.60% 64.31% 73.37% 48.20%
Net Working Capital to Revenue		 2,507.83% 1,180.84% 471.35% 196.05% 77.75% 292.98% 140.38% 51.41% 23.90% 73.37% 48.20%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.55) ($0.44) ($3.70) ($4.90) ($0.18) ($1.00) $0.02 ($0.03) ($0.76) ($0.45)
Adjusted Weighted Average Basic Shares Outstanding		 46.07M 45.34M 46.48M 4.65M 4.68M 51.81M 9.48M 9.49M 9.49M 10.65M 21.31M
Adjusted Diluted Earnings per Share		 ($0.54) ($0.55) ($0.44) ($3.70) ($4.90) ($0.18) ($1.00) $0.02 ($0.03) ($0.76) ($0.45)
Adjusted Weighted Average Diluted Shares Outstanding		 46.07M 45.34M 46.48M 4.65M 4.68M 51.81M 9.48M 9.49M 9.49M 10.65M 21.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.76) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.06M 42.42M 42.42M 4.27M 4.56M 91.78M 9.25M 9.45M 9.49M 17.18M 17.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -16 -13 -11 -14 -7.99 -5.69 1.06 1.14 -5.03 -6.80
Normalized NOPAT Margin		 -573.94% -814.68% -340.28% -205.61% 0.00% -2,321.80% -165.48% 8.32% 7.94% -98.87% -135.39%
Pre Tax Income Margin		 -850.26% -1,237.42% -531.39% -331.97% 0.00% -4,704.94% -283.28% 1.61% -1.91% -158.56% -192.75%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -14.46 -10.02 -8.03 -6.42 -8.71 -5.98 -3.58 0.99 0.79 -1.91 -60.77
NOPAT to Interest Expense		 -10.10 -7.03 -5.61 -4.50 -6.10 -3.40 -2.58 0.71 0.54 -1.77 -42.50
EBIT Less CapEx to Interest Expense		 -14.50 -10.11 -8.03 -6.43 -8.72 -5.98 -3.58 0.99 0.79 -1.91 -60.77
NOPAT Less CapEx to Interest Expense		 -10.14 -7.12 -5.61 -4.50 -6.11 -3.40 -2.58 0.71 0.54 -1.77 -42.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Verrica Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Verrica Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Verrica Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$17.89 million in 2025, rising from -$4.46 million in 2017. The previous period was -$76.58 million in 2024. See Verrica Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Verrica Pharmaceuticals' total operating income in 2025 was -$12.19 million, based on the following breakdown:
  • Total Gross Profit: $33.39 million
  • Total Operating Expenses: $45.57 million

Over the last 8 years, Verrica Pharmaceuticals' total revenue changed from $0.00 in 2017 to $35.58 million in 2025, a change of 3,557,700,000.0%.

Verrica Pharmaceuticals' total liabilities were at $22.39 million at the end of 2025, a 65.0% decrease from 2024, and a 3,534.4% increase since 2017.

In the past 8 years, Verrica Pharmaceuticals' cash and equivalents has ranged from $8.66 million in 2017 to $69.55 million in 2023, and is currently $30.15 million as of their latest financial filing in 2025.

Over the last 8 years, Verrica Pharmaceuticals' book value per share changed from -2.47 in 2017 to 2.61 in 2025, a change of -205.5%.


Related Companies

Financial statements for NASDAQ:VRCA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A better retirement stock than Berkshire?
Whitney Tilson - the analyst CNBC called 'The Prophet' for early calls on Netflix, Apple, and Amazon - says he...
Stansberry Research | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel